Rituximab and subcutaneous 2-chloro-2'-deoxyadenosine as therapy in untreated and relapsed Waldenström's macroglobulinemia

D. Laszlo, G. Andreola, L. Rigacci, A. Fabbri, C. Rabascio, A. Pinto, M. Negri, G. Martinelli

Research output: Contribution to journalArticle


With the aim to assess the efficacy of subcutaneous cladribine in combination with rituximab, 29 newly diagnosed/pretreated WM patients were enrolled in a multicenter phase II trial. Intended therapy consisted of rituximab on day 1 followed by s.c. cladribine 0.1 mg/kg for 5 consecutive days, administered monthly for 4 cycles. The expression of genes involved in cladribine metabolism was evaluated. With a median follow-up of 50 months the ORR rate observed was 89.6% without any difference between newly or pretreated patients (P = .522). The therapy was well tolerated; no major infections were observed, no patients developed transformation to high-grade NHL nor myelodysplasia. Low expression levels of hCNT1 correlated with the failure to achieve a CR (P = .024). The combination of rituximab/cladribine is safe and effective in WM patients requiring treatment. The pharmacogenomic analysis suggests that hCNT1 might be beneficial in predicting clinical response to such a combination treatment.

Original languageEnglish
Pages (from-to)130-132
Number of pages3
JournalClinical Lymphoma, Myeloma and Leukemia
Issue number1
Publication statusPublished - Feb 1 2011


ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Cite this